why choose us

Clinical Trials Search

Showing 9,380 of 132,963 result(s)
Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Status: NOT_YET_RECRUITING

Condition: Locally Advanced Adrenal Cortex Carcinoma

Interventions: Given IV

Date: 2023-08-17

Electronic Medical Record-Based Nudge to Reduce SLNB

Status: COMPLETED

Condition: Breast Cancer

Interventions: The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer.
The nudge flag can pop u

Date: 2023-08-17

MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Status: Completed

Condition: Arteriosclerosis

Interventions: MK-0616 20 mg tablet taken by mouth.

Date: 2023-08-17

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+;HER2- Advanced Breast Cancer

Status: Completed

Condition: Breast Cancer

Interventions: Patients will be treated with OP-1250 once daily on a 4 week (28 day) cycle

Date: 2023-08-17

Tele-video to Improve Daily Activity

Status: Completed

Condition: Physical Inactivity

Interventions: Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term acti

Date: 2023-08-17

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Status: NOT_YET_RECRUITING

Condition: Diffuse Large B Cell Lymphoma

Interventions: Allogeneic chimeric antigen receptor T cells (CAR-T) targeting both CD19 and CD20

Date: 2023-08-17

Aging Well Through Interactions and Scientific Education - Action Plan (AgeWISE-AP)

Status: NOT_YET_RECRUITING

Condition: Cognitive Aging

Interventions: 20-week program designed to provide education and individualized planning with a goal of improving brain health.

Date: 2023-08-17

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Status: Completed

Condition: Solid Tumors With HRAS Alterations

Interventions: Oral administration

Date: 2023-08-17

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Status: NOT_YET_RECRUITING

Condition: Chronic HIV Infection

Interventions: 100 mcg and 300 mcg

Date: 2023-08-17

JAK;STAT Inhibition in CNS Kohlmeier-Degos Disease

Status: Completed

Condition: Kohlmeier Degos Disease With Neurologic Involvement

Interventions: Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.

Date: 2023-08-17